Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.404 Factor de Impacto de 5 años: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v18.i6.30
pages 525-544

FcR-Mediated Inhibition of Cell Activation and Other Forms of Coinhibition

Colin C. Anderson
Department of Microbiology and Immunology, The University of Western Ontario, London, Ontario, Canada, N6A 5C1
Nicholas R. StC. Sinclair
Department of Microbiology and Immunology, The University of Western Ontario, London, Ontario, Canada, N6A 5C1


The tripartite inactivation model proposed that coaggregation of the B cell antigen receptor (BCR) with the Fc receptor (FcR) by antigen and specific IgG antibody complexes explained the Fc-dependent inhibition of immune responses by antibody. This model has since been substantiated by many observations and its impact on studies of immune regulation has been threefold: (1) IgG antibody, via FcγRIIB, mediates inhibition of cell activation in many cell types, demonstrating the general importance of this mechanism in immune regulation; (2) FcγRIIB was the first receptor described that regulates immune responses by coinhibition, that is, regulation as a result of interaction between activating receptors (BCR, TCR, FcεRI, FcγRIII, FcγRIIA) and inhibitory receptors (FcγRIIB, CTLA4, CD5, CD22, p58/70/140 KIR, gp49Bl/gp91, Ly49A/C/E/F/G, NKG2-A/B, APCR, Fas (CD95), TGFβ-R, TNF-R, IFNγ-R, and others). The list of coinhibitors is expanding, just as the list of costimulators has grown. Tolerance through multiple coinhibitors implies that Signal 1 alone is not tolerogenic; and (3) Studies of FcγRIIB coinhibitory mechanisms have pointed the way to potential general inhibitory signaling pathways used by many receptors, involving the competing effects of various kinases and phosphatases, and other competitive events. Investigations of FcγRIIB physiologic function and of other coinhibitory receptors, together with recent biochemical analyses, give an initial understanding of the biology of these inhibitory receptors. Paradoxes within and between theoretical constructs, functional observations, and mechanistic studies point to critical questions for future study.

Articles with similar content:

Natural IgM and the Development of B Cell-Mediated Autoimmune Diseases
Critical Reviews™ in Immunology, Vol.36, 2016, issue 2
Nicole Baumgarth, Trang T. T. Nguyen
Genetic Requirements for the Development and Differentiation of lnterleukin-17-Producing γδ T Cells
Critical Reviews™ in Immunology, Vol.32, 2012, issue 1
Sandra M. Hayes, Renee M. Laird
Signal Integration Following Toll-like Receptor Triggering
Critical Reviews™ in Immunology, Vol.22, 2002, issue 3
Alexander Dalpke, Klaus Heeg
Expression and Function of Fc Receptors in the Thymus
Critical Reviews™ in Immunology, Vol.15, 1995, issue 3-4
Georges Leclercq , Jean Plum
Targeting OX40 and OX40L for the Treatment of Autoimmunity and Cancer
Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Andrew D. Weinberg, William L. Redmond